Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.
Retinoid for oral treatment of severe cases of psoriasis and of disorders of keratinization
The excipients are microcrystalline cellulose, nonatetraenoic acid, gelatin, glucose liquid spray-dried,
sodium ascorbate and the colourants iron oxide black (E172), iron oxide red (E172), iron oxide yellow
Neotigason 10mg capsules are oval in shape and have an opaque white body and an opaque brown
cap with ‘Actavis‘printed on the cap and ‘10’ printed on the capsule body. The capsules are No. 4 in
Neotigason 25mg capsules are oval in shape and have an opaque yellow body and an opaque brown
cap with ‘Actavis‘ printed on the cap and ‘25’ printed on the capsule body. The capsules are No. 1 in
Properties and effects
Acitretin, the active ingredient of Neotigason, is a synthetic aromatic analogue of retinoic acid. In
preclinical investigations of the tolerability of acitretin, no relevant mutagenic or carcinogenic effects
were found, nor was there any evidence of direct liver toxicity. Acitretin was found to be highly
Clinical trials confirmed that, in psoriasis and disorders of keratinization, acitretin brought about
normalization of epidermal cell proliferation, differentiation and cornification, while the side effects
were, in general, tolerable. The effect of Neotigason is purely symptomatic; the mechanism of action
Acitretin reaches peak plasma concentration 1-4 hours after ingestion of the medicine. Bioavailability
of orally administered acitretin is best when the medicine is taken together with food. Bioavailability of
a single dose is approximately 60%, but this may vary considerably from one patient to another
Acitretin is highly lipophilic and penetrates readily into body tissues. Protein binding of acitretin
exceeds 99%. In animal studies, acitretin passed the placental barrier in quantities sufficient to
produce foetal malformations. Due to its lipophilic nature, it can be assumed that acitretin passes into
Acitretin is metabolized by isomerization into its 13-cis isomer (cis
acitretin), by glucuronidation and
Multiple-dose studies in patients aged 21-70 years showed an elimination half-life of approximately 50
hours for acitretin and 60 hours for its main metabolite in plasma, cis
acitretin, which is also a
teratogen. From the longest elimination half-life observed in these patients for acitretin (96 hours) and
acitretin (123 hours), and assuming linear kinetics, it can be predicted that more than 99% of the
medicine is eliminated within 36 days after cessation of long-term therapy. Furthermore, plasma
concentrations of acitretin and cis
acitretin dropped below the sensitivity limit of the assay (<6 ng/ml)
within 36 days following cessation of treatment. Acitretin is excreted entirely in the form of its
metabolites, in approximately equal parts via the kidneys and the bile.
Disorders of keratinization, such as ichthyotic disorders, palmoplantar keratoderma, Darier's
Other dermatoses responsive to etretinate.
Dosage and administration
Because there are differences in the absorption and rate of metabolism of acitretin, the dosage must
be individually adjusted. The capsules should preferably be taken once daily with a meal, or with milk.
The initial daily dosage,
mg (i.e. 1 capsule 25 mg) or 30 mg (i.e. 3 capsules 10 mg) for about 2-4
weeks may give satisfactory therapeutic results.
The maintenance dose
must be based on clinical efficacy and tolerability. In general, a daily dosage
of 25-50 mg taken for a further 6-8 weeks achieves optimal therapeutic results.
It may be necessary in some cases to increase the dose up to a maximum of 75 mg/day (i.e. 3
Therapy can be terminated in patients with psoriasis
whose lesions have resolved sufficiently.
Relapses should be treated as described above.
In disorders of keratinization,
maintenance therapy is usually needed, though the lowest possible
dosage should be given. This may be less than 20 mg/day and should not exceed 50 mg/day.
In view of possible severe side effects associated with long-term treatment, the risk should be
carefully weighed against the therapeutic benefit. Acitretin should be used only when all alternative
The dosage should be established according to bodyweight. The daily dosage
is about 0.5 mg/kg.
Higher doses (up to 1 mg/kg daily) may be necessary in some cases for limited periods, but only up to
a maximum of 35 mg/day. The maintenance dose
should be kept as low as possible in view of
When Neotigason is used in combination with other types of therapy, it may be possible - depending
on the patient’s individual response - to reduce the dosage of Neotigason.
Standard topical treatments can generally be continued and do not interfere with Neotigason.
Neotigason is highly teratogenic and must not be used by women who are pregnant. The same
applies to women of childbearing potential unless strict contraception is practised 4 weeks before,
during and for 2 years after treatment (see below).
Women of childbearing potential must not receive blood from patients being treated with Neotigason.
Donation of blood by a patient being treated with Neotigason is prohibited during and for two years
after completion of treatment with Neotigason.
Neotigason is contraindicated in patients with severely impaired liver or kidney function and in patients
with chronic abnormally elevated blood lipid values.
Since both Neotigason and tetracyclines can cause increased intracranial pressure, their combined
An increased risk of hepatitis has been reported to result from combined use of methotrexate and
etretinate. Consequently, the combination of methotrexate with Neotigason is also contraindicated.
Concomitant administration of Neotigason and vitamin A or other retinoids is contraindicated due to
Neotigason is contraindicated in cases of hypersensitivity to the preparation (acitretin or excipients) or
Neotigason should only be prescribed by physicians who are experienced in the use of systemic
retinoids and understand the risk of teratogenicity associated with acitretin therapy.
Alcohol (in drinks, food or medicines) must not be ingested during treatment with Neotigason by
women of childbearing age, as clinical evidence has shown that etretinate can be formed with
concurrent ingestion of acitretin and alcohol. The mechanism of this metabolic process has not been
defined, so it is not clear whether other interacting agents are also possible. Etretinate is highly
teratogenic and has a longer half life that acitretin. Ethanol should be avoided for 2 months after
Hepatic function should be checked before starting treatment with Neotigason, every 1-2 weeks for
the first 2 months after commencement and then every 3 months during treatment. If abnormal results
are obtained, weekly checks should be instituted. If hepatic function fails to return to normal or
deteriorates further, Neotigason must be withdrawn. In such cases it is advisable to continue
monitoring hepatic function for at least 3 months.
Serum cholesterol and serum triglycerides (fasting values) must be monitored, especially in high-risk
patients (disturbances of lipid metabolism, diabetes mellitus, obesity, alcoholism) and during long-term
In diabetics, retinoids can either improve or worsen glucose tolerance. Blood-sugar levels must
therefore be checked more frequently than usual in the early stages of treatment.
In adults receiving long-term treatment with Neotigason, appropriate examinations should be
periodically performed in view of possible ossification abnormalities (see Undesirable effects). If such
disorders arise, the continuation of therapy should be discussed with the patient on the basis of a
In children, growth parameters and bone development must be closely monitored.
Decreased night vision has been reported with Neotigason therapy. Patients should be advised of this
potential problem and warned to be cautious when driving or operating any vehicle at night. Visual
problems should be carefully monitored (see Undesirable effects).
Low dosed progesterone preparations (minipills) may be an inadequate method of contraception
It should be emphasized that, at the present time, not all the consequences of life-long administration
For male patients treated with Neotigason, available data, based on the level of maternal exposure
from the semen and seminal fluid indicate a minimal, if any, risk of teratogenic effects.
Pregnancy, nursing mothers
Neotigason is highly teratogenic. Its use is contraindicated not only in pregnant women and women
who might become pregnant during or within 2 years of the cessation of treatment, but in all women of
childbearing potential. The risk of giving birth to a deformed child is exceptionally high if Neotigason is
taken before or during pregnancy, no matter for how long or at what dosage. Foetal exposure to
Neotigason always involves a risk of congenital malformation.
Neotigason is contraindicated in every woman of childbearing potential unless each of the following
1. The patient is suffering from a severe disorder of keratinization which is resistant to standard
2. She can be relied on to understand and follow the physician’s instructions.
3. She is capable of taking the stipulated contraceptive measures reliably and without fail.
4. It is absolutely essential that every woman of childbearing potential who is to undergo treatment
with Neotigason uses an effective contraceptive (preferably 2 complementary methods) without
interruption for four weeks before, during and for 2 years after the discontinuation of treatment
with Neotigason. Primary contraceptive method is a combination hormonal contraceptive product
or an intrauterine device and it is recommended that a condom or a diaphragm (cap) is also used.
Low dose progesterone-only products (minipills) are not recommended due to indications of
possible interference with their contraceptive effect.
5. Therapy should not begin until the second or third day of the next normal menstrual period.
6. A negative pregnancy test result must be obtained as minimum, one week before commencement
of treatment. (It is advisable to perform additional pregnancy tests at monthly intervals during
therapy and at 1-3 monthly intervals after stopping therapy.)
7. Before therapy with Neotigason is instituted, the physician must give patients of childbearing
potential detailed verbal and written information about the precautions to be taken, the risk of very
severe foetal malformation, and the possible consequences if pregnancy occurs during the course
of treatment with Neotigason or within 2 years of discontinuing therapy.
8. The same effective and uninterrupted contraceptive measures must be taken every time therapy
is repeated, however long the intervening period may have been, and must be continued for 2
9. Should pregnancy occur, in spite of these precautions, during treatment with Neotigason or up to
2 years after its discontinuation there is a high risk of severe malformation of the fetus (e.g.
10. She must avoid alcohol consumption during treatment and for 2 months after stopping treatment.
Neotigason must not be given to nursing mothers.
Side effects are seen in most patients receiving Neotigason. However, they usually disappear when
the dosage is reduced or the medicine is withdrawn. An initial worsening of psoriasis symptoms is
sometimes seen at the beginning of the treatment period.
The most frequent side effects observed are symptoms of hypervitaminosis A, e.g. dryness of the lips,
which can be alleviated by application of a fatty ointment.
Mucous membranes and transitional epithelia become dried out or exhibit inflammatory lesions. This
has occasionally led to nosebleeds and rhinitis, to ocular disturbances (xerophthalmia, conjunctivitis)
and may lead to intolerance of contact lenses. Corneal ulcerations have been observed rarely.
Cheilitis, rhagades of the corner of the mouth, dry mouth and thirst may also occur. Occasionally,
stomatitis, gingivitis and taste disturbances have been reported.
Increased incidence of vulvo-vaginitis due to Candida albicans has been noted during treatment with
Thinning of the skin and scaling may occur all over the body, particularly on the palms and soles.
Sticky skin, dermatitis, erythema and pruritus have been frequently reported.
Increased hair loss, nail fragility and paronychia are frequently observed. Occasionally, bullous
eruption and abnormal hair texture have been reported. Rarely, patients may experience
These side effects are in general reversible after discontinuation of Neotigason treatment.
Headache is occasionally reported although intracranial hypertension (Pseudotumor cerebri) is rare.
Patients with severe headache, nausea, vomiting, and visual disturbances should discontinue
Neotigason immediately and be referred for neurologic evaluation and care. Occasionally, blurred
vision and impaired night vision have been noted (see Precautions).
Muscle, joint and bone pain have also been occasionally reported. Maintenance treatment may result
in progression of existing spinal hyperostosis, in appearance of new hyperostotic lesions and in
extraskeletal calcification, as has been observed in long-term systemic treatment with retinoids.
Occasionally, peripheral oedema and flushing have been reported. Gastro-intestinal disorders,
hepatitis and icterus have been observed rarely.
Transient, usually reversible elevation of transaminases and alkaline phosphatases has been
During treatment with high doses of Neotigason, reversible elevation of serum triglycerides and serum
cholesterol has occurred, especially in high-risk patients (disturbances of lipid metabolism, diabetes
mellitus, obesity, alcoholism). An associated risk of atherogenesis cannot be ruled out if these
Peripheral neuropathy may occur rarely under Neotigason treatment.
Concomitant administration of vitamin A and other retinoids must be avoided because of the risk of
Investigations into the effect of Neotigason on the protein binding of anticoagulants of the coumarin
type (warfarin) revealed no interaction.
If Neotigason is given concurrently with phenytoin, it must be remembered that Neotigason partially
Low dose progesterone-only products (minipills) may be an inadequate method of contracepation
Methotrexate, tetracyclines: see Contraindications
Further interactions between Neotigason and other substances (e.g. digoxin, cimetidine, combined
estrogen/progestogen oral contraceptives) have not been observed so far.
In a study with healthy volunteers concurrent intake of a single dose of acitretin together with ethanol
led to the formation of etretinate. This was already observed in vitro. In recent investigations, the
formation of etretinate has also been observed in certain patients treated with Neotigason. Until this
phenomenon has been fully explained, the pharmacokinetic behaviour of etretinate must be taken into
account. Therefore, since the elimination half-life of etretinate is approximately 120 days,
contraceptive measures must be taken for 2 years after completion of Neotigason treatment (see
In the event of acute overdose, Neotigason must be withdrawn at once. Further special measures are
unnecessary because of the low acute toxicity of the preparation. Symptoms of overdose are identical
to an acute hypervitaminosis A, i.e. headache and vertigo.
The product is sensitive to moisture. Therefore store in the original package.
This medicine should not be used after the expiry date shown on the pack.
Capsules 10 mg 100’s
Name and Address
Pharmacy Retailing NZ Ltd trading as Healthcare Logistics
Date of Preparation
Reference: International Core Data Sheet Version 2, 24-04-2009
Boldmere SC 11 Club Championships at Stechford (25m) Boldmere SC (BLDM) 11 50m Butterfly, Female, 10/11 years, HDW 01:15.0026 100m Freestyle, Male, 12 years and over, 01:10.947 100m Breaststroke, Female, 12 years and 01:44.0018 50m Backstroke, Male, 10/11 years, HDW 00:39.9818 50m Backstroke, Male, 10/11 years, HDW 01:00.0018 50m Backstroke, Male, 10/11 years, HDW 01:04.7218 50m Back
SUMMARY OF PRODUCT CHARACTERISTICS NAME OF THE MEDICINAL PRODUCT Intrinsa 300 micrograms/24 hours transdermal patch 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each patch of 28 cm2 contains 8.4 mg testosterone and provides 300 micrograms of testosterone per 24 hours. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL Transdermal patch. Thin, clear, o